The Deception and Fallacies of Sponsored Randomized Prospective Double-Blinded Clinical Trials: The Bisphosphonate Research Example

International Journal of Oral and Maxillofacial Implants

Volumn 29, Issue 1, 2014, Pages e37-e44

  Marx, Robert E ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

intravenous bisphosphonates; oral bisphosphonates; randomized clinical trials

Indexed keywords

ALENDRONIC ACID; ANOREXIGENIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; LACTONE; ROFECOXIB; SULFONE;

ARTICLE; CHEMICALLY INDUCED DISORDER; DECEPTION; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG SURVEILLANCE PROGRAM; ETHICS; FEMALE; FEMUR FRACTURE; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; HISTORY; HUMAN; JAW OSTEONECROSIS; LUNG TUBERCULOSIS; MALE; METHODOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; RESEARCH; RETROSPECTIVE STUDY; STANDARD; UNITED STATES;

ALENDRONATE; APPETITE DEPRESSANTS; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; DECEPTION; DIPHOSPHONATES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FEMORAL FRACTURES; HISTORY, 20TH CENTURY; HUMANS; LACTONES; MALE; PHARMACOVIGILANCE; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; RESEARCH REPORT; RESEARCH SUPPORT AS TOPIC; RETROSPECTIVE STUDIES; SULFONES; TUBERCULOSIS, PULMONARY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84900031338     PISSN: 08822786     EISSN: 19424434     Source Type: Journal    
DOI: 10.11607/jomi.te40     Document Type: Article

References (51)

1. 1. US Preventive Services Task Force Procedure Manual. 4.3. Assessing Evidence at the Individual Study Level. www.uspreventiveservicestaskforce.org/uspstf08/methods/procmanual4.htm. Accessed April 2012.
2. 2. Topol EJ. Failing the public health: Rofecoxib, Merck, and the FDA. N Engl J Med 2004;351:1707–1709.
3. 3. Bombardier C, Laine L, Reicin A, et al; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of Rofecoxib and Naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520–1528.
4. 4. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofacial Surg 2005;63:1567–1575.
5. 5. Ruggerio SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates. A review of 63 cases. J Oral Maxillofac Surg 2004;62: 527–534.
6. 6. Edwards BJ, Gounder M, McKoy JM, et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: Bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 2008;9:1166–1172.
7. 7. Marx RE, Cillo JE, Ulloa J. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention and treatment. J Oral Maxillofac Surg 2007;65:2397–2410.
8. 8. Hill AB. The clinical trial. N Engl J Med 1952;227:113–119.
9. 9. Le Fanu J. The Rise and Fall of Modern Medicine. New York: Carroll & Graf, 2002:26–29.
10. 10. Bradford Hill A. A pilot in the first World War. Br Med J 1983; 287:1947–1949.
11. 11. Hill AB. Suspended judgment. Memories of the British streptomycin trial in tuberculosis. The first randomized clinical trial. Control Clin Trials 1990;11:77–79.
12. 12. Green FHK. The clinical evaluation of remedies. Lancet 1954; 267:1085–1090.
13. 13. Dunn PM. James Lind of Edinburgh and the treatment of scurvy. Arch Dis Child Fetal Neonatal Ed 1997;76:F64–F65.
14. 14. Croflon J, Mitchison DA. Streptomycin resistance in pulmonary tuberculosis. Br Med J 1948;2:1009–1015.
15. 15. Edwards MH, McCrae FC, Young-Min SA. Alendronate-related femoral disphysis fracture – What should be done to predict and prevent subsequent fracture of the contralateral side? Osteoporosis Int 2010;21:701–703.
16. 16. Das De S, Setiobudi T, Shen L, Das De S. A rational approach to management of alendronate-related subtrochantaric fractures. J Bone Joint Surg Br 2010;92:679–686.
17. 17. Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23:826–836.
18. 18. Dimopoulos MA, Kastritis E, Anagnostopolous A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid. Hematologica 2006;91: 968–971.
19. 19. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 2005;23:8580–8587.
20. 20. Liberman UA, Weiss SR, Broll J, et al; Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437–1443.
21. 21. Adami S, Isaia G, Luisetto G, et al; ICARO Study Group. Osteoporosis treatment and fracture incidence: The ICARO longitudinal study. Osteoporosis Int 2008;19:1219–1223.
22. 22. Jarwen TLN, Sievanen H, Khan KM, Heinonen A, Kannus S. Shifting the focus in fracture prevention from osteoporosis to falls. Br Med J 2008;336:124–126.
23. 23. Alonso-Cuello P, Garcia-Franco AL, Guyatl C, Moynihan R. Drugs for preosteoporosis: Prevention or disease mongering. Br Med J 2008;336:126–129.
24. 24. Boyne PJ, Lilly LC, Marx RE, et al. De novo induction by recombinant human bone morphogentic protein-2 (rhBMP) in maxillary sinus floor augmentation. J Oral Maxillofac Surg 2008;63:693–707.
25. 25. Marx RE. Pamidronate (Aredia) and zolendronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003;615–1117.
26. 26. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates. A review of 63 cases. J Oral and Maxillofac Surg 2004;62:527–534.
27. 27. Tarassoff P, Csermak K. Avascular necrosis of the jaws. Risk factors in metastatic cancer patients. J Oral Maxillofac Surg 2003;61:1238–1239.
28. 28. Ruggerio SL, Gialow J, Marx RE, et al. Practical guidelines of the prevention, diagnosis and treatment of osteonecrosis of the jaws in patient with cancer. J Oncol Pract 2005;2:7–14.
29. 29. Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: A case-control study. J Oral Maxillofac Surg 2008;66:625–631.
30. 30. FDA, Oncologic Drugs Advisory Committee Meeting. Aredia/Zometa. Questions to the Committee, March 4, 2005. http://www.fda.gov/ohrms/dockets/ac/05/questions/2005-4095Q1_02_Iressa-Questions.pdf. Accessed April 2012.
31. 31. FDA Zometa. http://www.fda.gov/Safety/Medwatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm152865.htm. Accessed April 2012.
32. 32. FDA Aredia. http://www.fda.gov/Safety/Medwatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm152862.htm. Accessed April 2012.
33. 33. Novartis Pharmaceutical Corporation. Approved ONJ external med slide deck. ONC ver Mar 17, 06 ppt, 2006.
34. 34. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535–1541.
35. 35. Bone HG, Hoskeng D, Devogalaer JP, et al. Ten years experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2001;350:1189–1199.
36. 36. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: The fracture intervention trial long-term extension (FLEX): A randomized trial. JAMA 2006;296:2227–2938.
37. 37. Etminan M, Aminzadek K, Matthew IR, Brophy JM. Use of oral bisphosphonates and the risk of aseptic osteonecrosis: A nested case-control study. J Rheumatol 2008;35:691–695.
38. 38. Gómez V, Xiao SY. Alendronate-induced esophagitis in an elderly woman. Int J Clin Exp Pathol 2009;2:200–203.
39. 39. Carnahan RM, Lund BC, Perry PJ, Chrischilles EA. The concurrent use of anticholinergics and cholenesterase inhibitors: Rare event of common practice? J Am Geriatr Soc 2004;52:2082–2087.
40. 40. Starr JM, Whalley LJ. Drug-induced dementia: Incidence, management and prevention. Drug Safety 1994;11:310–317.
41. 41. FDA directs ADHD drug manufacturers to notify patients about cardiovascular adverse events and psychiatric adverse events. FDA press release, February 21, 2007. http://www.fda.gov/NewsEvents/PressAnnouncements/2007/ucm108849.htm. Accessed 25 April 2012.
42. 42. Black DM, Delmas PD, Eastell R, et al; HORIZON Pivotal Fracture Trial. Once yearly zoledronic acid 5 mg for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–1822.
43. 43. Lasseter KC, Porras AG, Denker A, Santhanagopal A, Daifotis A. Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates. Clin Drug Investig 2005;25:107–114.
44. 44. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369–376.
45. 45. Khosla S, Burr D, Cauley J, et al; American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw. Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479–1491.
46. 46. Jeffcoat MK. Safety of oral bisphosphonates: Controlled studies on alveolar bone. Int J Oral Maxillofac Implants 2006;20: 349–353.
47. 47. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghost writing in publications related to rofecoxib. JAMA 2008;299:1800–1812.
48. 48. Flanagin A, Carey LA, Fontanarosa PB, et al. Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. JAMA 1998;280:222–224.
49. 49. Mowatt G, Shirian L, Grimshaw JM, et al. Prevalence of honorary and ghost authorship in Cochrane reviews. JAMA 2002;287:2769–2771.
50. 50. Angell M. The Truth About the Drug Companies. How They Deceive Us and What to Do About It. New York: Random House, 2005.
51. 51. Petersen M. Our Daily Meds. New York: Sarah Cruchton Books/Farrar, Strauss, and Geroux, 2008.